Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Seliger

Showing results (301-310 of 304) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 304 results.
Nature Cancer|July 7, 2025
IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR<sup>+</sup>HER2<sup>-</sup> breast cancer via CX3CR1<sup>+</sup> macrophagesGiulia Petroni, Claudia Galassi, Kenneth H Gouin, et al.
Journal for Immunotherapy of Cancer|March 7, 2025
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocolsTricia R Cottrell, Michael T Lotze, Alaa Ali, et al.
Oncotarget|December 25, 2014
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, et al.
Journal of Translational Medicine|December 16, 2011
Defining the critical hurdles in cancer immunotherapyBernard A Fox, Dolores J Schendel, Lisa H Butterfield, et al.
Pageof 31

Showing results (301-310 of 304) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 304 results.
Nature Cancer|July 7, 2025
IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR<sup>+</sup>HER2<sup>-</sup> breast cancer via CX3CR1<sup>+</sup> macrophagesGiulia Petroni, Claudia Galassi, Kenneth H Gouin, et al.
Journal for Immunotherapy of Cancer|March 7, 2025
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocolsTricia R Cottrell, Michael T Lotze, Alaa Ali, et al.
Oncotarget|December 25, 2014
Classification of current anticancer immunotherapiesLorenzo Galluzzi, Erika Vacchelli, José-Manuel Bravo-San Pedro, et al.
Journal of Translational Medicine|December 16, 2011
Defining the critical hurdles in cancer immunotherapyBernard A Fox, Dolores J Schendel, Lisa H Butterfield, et al.
Pageof 31